Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive · Inflammatory Myofibroblastic Tumor · Other Solid Tumor
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Institut Gustave Roussy, Paris, France
Contact: Study coordinator (Charlotte Rigaud, MD) · charlotte.rigaud@gustaveroussy.fr · +33 1 42 11 42 11Contact: Principal Investigator (Veronique Minard, Prof Dr)Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, Netherlands
Contact: Study coordinator (Maaike Boonstra, MSc) · m.boonstra@prinsesmaximacentrum.nl · +31 65000 66 72Contact: Study coordinator (Gertruud Bakker, PhD) · G.C.M.Bakker-7@prinsesmaximacentrum.nl · +31 6 5000 61 79Contact: Principal Investigator (N.K.A van Eijkelenburg, MD)
Study leads
Michel Zwaan, Prof
Principal Investigator
Princess Maxima Center for Pediatric Oncology in The Netherlands